Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2015

A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma: the Non-Hodgkin’s Lymphoma Classification Project. Blood 1997;89:3909–3918.

A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma: the Non-Hodgkin’s Lymphoma Classification Project. Blood1997;89:3909–3918. )| false
• Search Google Scholar
• Export Citation

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5–29.

SiegelRLMillerKDJemalA. Cancer statistics, 2015. CA Cancer J Clin2015;65:5–29. )| false
• Search Google Scholar
• Export Citation

Hallek M, Cheson BD, Catovsky D. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–5456.

HallekMChesonBDCatovskyD. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood2008;111:5446–5456. )| false
• Search Google Scholar
• Export Citation

Tsimberidou AM, Wen S, O’Brien S. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas MD Anderson Cancer Center. J Clin Oncol 2007;25:4648–4656.

TsimberidouAMWenSO’BrienS. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas MD Anderson Cancer Center. J Clin Oncol2007;25:4648–4656. )| false
• Search Google Scholar
• Export Citation

Rawstron AC. Monoclonal B-cell lymphocytosis. Hematology Am Soc Hematol Educ Program 2009:430–439.

RawstronAC. Monoclonal B-cell lymphocytosis. Hematology Am Soc Hematol Educ Program2009:430–439. )| false
• Search Google Scholar
• Export Citation

Rawstron AC, Bennett FL, O’Connor SJ. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 2008;359:575–583.

RawstronACBennettFLO’ConnorSJ. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med2008;359:575–583. )| false
• Search Google Scholar
• Export Citation

Baliakas P, Iskas M, Gardiner A. Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data. Am J Hematol 2014;89:249–255.

BaliakasPIskasMGardinerA. Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data. Am J Hematol2014;89:249–255. )| false
• Search Google Scholar
• Export Citation

Woyach JA, Ruppert AS, Lozanski G. Association of disease progression on ibrutinib therapy with the acquisition of resistance mutations: a single-center experience of 267 patients [abstract]. J Clin Oncol 2014;32(15_suppl):Abstract 7010.

WoyachJARuppertASLozanskiG. Association of disease progression on ibrutinib therapy with the acquisition of resistance mutations: a single-center experience of 267 patients [abstract]. J Clin Oncol2014;32(15_suppl):Abstract 7010. )| false
• Search Google Scholar
• Export Citation

Thompson PA, Wierda WG, Ferrajoli A. Complex karyotype, rather than del(17p), is associated with inferior outcomes in relapsed or refractory CLL patients treated with ibrutinib-based regimens [abstract]. Blood 2014;124:Abstract 22.

ThompsonPAWierdaWGFerrajoliA. Complex karyotype, rather than del(17p), is associated with inferior outcomes in relapsed or refractory CLL patients treated with ibrutinib-based regimens [abstract]. Blood2014;124:Abstract 22. )| false
• Search Google Scholar
• Export Citation

Dicker F, Schnittger S, Haferlach T. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood 2006;108:3152–3160.

DickerFSchnittgerSHaferlachT. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood2006;108:3152–3160. )| false
• Search Google Scholar
• Export Citation

Put N, Konings P, Rack K. Improved detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide and interleukin-2 stimulation: a Belgian multicentric study. Genes Chromosomes Cancer 2009;48:843–853.

PutNKoningsPRackK. Improved detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide and interleukin-2 stimulation: a Belgian multicentric study. Genes Chromosomes Cancer2009;48:843–853. )| false
• Search Google Scholar
• Export Citation

Struski S, Gervais C, Helias C. Stimulation of B-cell lymphoproliferations with CpG-oligonucleotide DSP30 plus IL-2 is more effective than with TPA to detect clonal abnormalities. Leukemia 2009;23:617–619.

StruskiSGervaisCHeliasC. Stimulation of B-cell lymphoproliferations with CpG-oligonucleotide DSP30 plus IL-2 is more effective than with TPA to detect clonal abnormalities. Leukemia2009;23:617–619. )| false
• Search Google Scholar
• Export Citation

Heerema NA, Byrd JC, Dal Cin PS. Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) study. Cancer Genet Cytogenet 2010;203:134–140.

HeeremaNAByrdJCDal CinPS. Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) study. Cancer Genet Cytogenet2010;203:134–140. )| false
• Search Google Scholar
• Export Citation

Crespo M, Bosch F, Villamor N. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764–1775.

CrespoMBoschFVillamorN. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med2003;348:1764–1775. )| false
• Search Google Scholar
• Export Citation

Damle RN, Wasil T, Fais F. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840–1847.

DamleRNWasilTFaisF. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood1999;94:1840–1847. )| false
• Search Google Scholar
• Export Citation

Del Poeta G, Maurillo L, Venditti A. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 2001;98:2633–2639.

Del PoetaGMaurilloLVendittiA. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood2001;98:2633–2639. )| false
• Search Google Scholar
• Export Citation

Dohner H, Stilgenbauer S, Benner A. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910–1916.

DohnerHStilgenbauerSBennerA. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med2000;343:1910–1916. )| false
• Search Google Scholar
• Export Citation

Hallek M, Langenmayer I, Nerl C. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 1999;93:1732–1737.

HallekMLangenmayerINerlC. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood1999;93:1732–1737. )| false
• Search Google Scholar
• Export Citation

Hallek M, Wanders L, Ostwald M. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma 1996;22:439–447.

HallekMWandersLOstwaldM. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma1996;22:439–447. )| false
• Search Google Scholar
• Export Citation

Hamblin TJ, Davis Z, Gardiner A. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848–1854.

HamblinTJDavisZGardinerA. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood1999;94:1848–1854. )| false
• Search Google Scholar
• Export Citation

Hamblin TJ, Orchard JA, Ibbotson RE. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002;99:1023–1029.

HamblinTJOrchardJAIbbotsonRE. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood2002;99:1023–1029. )| false
• Search Google Scholar
• Export Citation

Ibrahim S, Keating M, Do KA. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001;98:181–186.

IbrahimSKeatingMDoKA. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood2001;98:181–186. )| false
• Search Google Scholar
• Export Citation

Orchard JA, Ibbotson RE, Davis Z. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004;363:105–111.

OrchardJAIbbotsonREDavisZ. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet2004;363:105–111. )| false
• Search Google Scholar
• Export Citation

Rassenti LZ, Huynh L, Toy TL. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351:893–901.

RassentiLZHuynhLToyTL. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med2004;351:893–901. )| false
• Search Google Scholar
• Export Citation

Wiestner A, Rosenwald A, Barry TS. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101:4944–4951.

WiestnerARosenwaldABarryTS. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood2003;101:4944–4951. )| false
• Search Google Scholar
• Export Citation

Bulian P, Shanafelt TD, Fegan C. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J Clin Oncol 2014;32:897–904.

BulianPShanafeltTDFeganC. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J Clin Oncol2014;32:897–904. )| false
• Search Google Scholar
• Export Citation

Tobin G, Thunberg U, Johnson A. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002;99:2262–2264.

TobinGThunbergUJohnsonA. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood2002;99:2262–2264. )| false
• Search Google Scholar
• Export Citation

Krober A, Bloehdorn J, Hafner S. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 2006;24:969–975.

KroberABloehdornJHafnerS. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol2006;24:969–975. )| false
• Search Google Scholar
• Export Citation

Krober A, Seiler T, Benner A. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100:1410–1416.

KroberASeilerTBennerA. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood2002;100:1410–1416. )| false
• Search Google Scholar
• Export Citation

Oscier D, Wade R, Davis Z. Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica 2010;95:1705–1712.

OscierDWadeRDavisZ. Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica2010;95:1705–1712. )| false
• Search Google Scholar
• Export Citation

Oscier DG, Gardiner AC, Mould SJ. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002;100:1177–1184.

OscierDGGardinerACMouldSJ. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood2002;100:1177–1184. )| false
• Search Google Scholar
• Export Citation

Gentile M, Mauro FR, Calabrese E. The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience. Br J Haematol 2005;130:549–557.

GentileMMauroFRCalabreseE. The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience. Br J Haematol2005;130:549–557. )| false
• Search Google Scholar
• Export Citation

Del Principe MI, Del Poeta G, Buccisano F. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood 2006;108:853–861.

Del PrincipeMIDel PoetaGBuccisanoF. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood2006;108:853–861. )| false
• Search Google Scholar
• Export Citation

Rassenti LZ, Jain S, Keating MJ. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008;112:1923–1930.

RassentiLZJainSKeatingMJ. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood2008;112:1923–1930. )| false
• Search Google Scholar
• Export Citation

Corcoran M, Parker A, Orchard J. ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia. Haematologica 2005;90:1078–1088.

CorcoranMParkerAOrchardJ. ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia. Haematologica2005;90:1078–1088. )| false
• Search Google Scholar
• Export Citation

Claus R, Lucas DM, Stilgenbauer S. Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol 2012;30:2483–2491.

ClausRLucasDMStilgenbauerS. Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol2012;30:2483–2491. )| false
• Search Google Scholar
• Export Citation

Claus R, Lucas DM, Ruppert AS. Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. Blood 2014;124:42–48.

ClausRLucasDMRuppertAS. Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. Blood2014;124:42–48. )| false
• Search Google Scholar
• Export Citation

Tam CS, O’Brien S, Wierda W. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975–980.

TamCSO’BrienSWierdaW. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood2008;112:975–980. )| false
• Search Google Scholar
• Export Citation

Tsimberidou AM, Tam C, Wierda W. Beta-2 microglobulin (B2M) is an independent prognostic factor for clinical outcomes in patients with CLL treated with frontline fludarabine, cyclophosphamide, and rituximab (FCR) regardless of age, creatinine clearance (CrCl) [abstract]. J Clin Oncol 2007;25:Abstract 7034.

TsimberidouAMTamCWierdaW. Beta-2 microglobulin (B2M) is an independent prognostic factor for clinical outcomes in patients with CLL treated with frontline fludarabine, cyclophosphamide, and rituximab (FCR) regardless of age, creatinine clearance (CrCl) [abstract]. J Clin Oncol2007;25:Abstract 7034. )| false
• Search Google Scholar
• Export Citation

Wierda WG, O’Brien S, Wang X. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol 2009;27:1637–1643.

WierdaWGO’BrienSWangX. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol2009;27:1637–1643. )| false
• Search Google Scholar
• Export Citation

Wierda WG, O’Brien S, Wang X. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 2007;109:4679–4685.

WierdaWGO’BrienSWangX. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood2007;109:4679–4685. )| false
• Search Google Scholar
• Export Citation

Shanafelt TD, Jenkins G, Call TG. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer 2009;115:363–372.

ShanafeltTDJenkinsGCallTG. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer2009;115:363–372. )| false
• Search Google Scholar
• Export Citation

Molica S, Mauro FR, Callea V. The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience. Haematologica 2010;95:464–469.

MolicaSMauroFRCalleaV. The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience. Haematologica2010;95:464–469. )| false
• Search Google Scholar
• Export Citation

Neilson JR, Auer R, White D. Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival. Leukemia 1997;11:1929–1932.

NeilsonJRAuerRWhiteD. Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival. Leukemia1997;11:1929–1932. )| false
• Search Google Scholar
• Export Citation

Austen B, Skowronska A, Baker C. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 2007;25:5448–5457.

AustenBSkowronskaABakerC. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol2007;25:5448–5457. )| false
• Search Google Scholar
• Export Citation

Tsimberidou AM, Tam C, Abruzzo LV. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer 2009;115:373–380.

TsimberidouAMTamCAbruzzoLV. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer2009;115:373–380. )| false
• Search Google Scholar
• Export Citation

Hallek M, Fischer K, Fingerle-Rowson G. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164–1174.

HallekMFischerKFingerle-RowsonG. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet2010;376:1164–1174. )| false
• Search Google Scholar
• Export Citation

Catovsky D, Richards S, Matutes E. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet 2007;370:230–239.

CatovskyDRichardsSMatutesE. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet2007;370:230–239. )| false
• Search Google Scholar
• Export Citation

Stilgenbauer S, Sander S, Bullinger L. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica 2007;92:1242–1245.

StilgenbauerSSanderSBullingerL. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica2007;92:1242–1245. )| false
• Search Google Scholar
• Export Citation

Wierda WG, O’Brien S, Wang X. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol 2011;29:4088–4095.

WierdaWGO’BrienSWangX. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol2011;29:4088–4095. )| false
• Search Google Scholar
• Export Citation

Pflug N, Bahlo J, Shanafelt TD. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood 2014;124:49–62.

PflugNBahloJShanafeltTD. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood2014;124:49–62. )| false
• Search Google Scholar
• Export Citation

Zenz T, Eichhorst B, Busch R. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010;28:4473–4479.

ZenzTEichhorstBBuschR. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol2010;28:4473–4479. )| false
• Search Google Scholar
• Export Citation

Stilgenbauer S, Schnaiter A, Paschka P. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123:3247–3254.

StilgenbauerSSchnaiterAPaschkaP. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood2014;123:3247–3254. )| false
• Search Google Scholar
• Export Citation

Gonzalez D, Martinez P, Wade R. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol 2011;29:2223–2229.

GonzalezDMartinezPWadeR. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol2011;29:2223–2229. )| false
• Search Google Scholar
• Export Citation

Rossi D, Cerri M, Deambrogi C. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009;15:995–1004.

RossiDCerriMDeambrogiC. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res2009;15:995–1004. )| false
• Search Google Scholar
• Export Citation

Woyach JA, Ruppert AS, Heerema NA. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol 2011;29:1349–1355.

WoyachJARuppertASHeeremaNA. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol2011;29:1349–1355. )| false
• Search Google Scholar
• Export Citation

Fabbri G, Rasi S, Rossi D. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011;208:1389–1401.

FabbriGRasiSRossiD. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med2011;208:1389–1401. )| false
• Search Google Scholar
• Export Citation

Puente XS, Pinyol M, Quesada V. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475:101–105.

PuenteXSPinyolMQuesadaV. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature2011;475:101–105. )| false
• Search Google Scholar
• Export Citation

Wang L, Lawrence MS, Wan Y. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011;365:2497–2506.

WangLLawrenceMSWanY. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med2011;365:2497–2506. )| false
• Search Google Scholar
• Export Citation

Quesada V, Conde L, Villamor N. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2012;44:47–52.

QuesadaVCondeLVillamorN. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet2012;44:47–52. )| false
• Search Google Scholar
• Export Citation

Rossi D, Fangazio M, Rasi S. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 2012;119:2854–2862.

RossiDFangazioMRasiS. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood2012;119:2854–2862. )| false
• Search Google Scholar
• Export Citation

Messina M, Del Giudice I, Khiabanian H. Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. Blood 2014;123:2378–2388.

MessinaMDel GiudiceIKhiabanianH. Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. Blood2014;123:2378–2388. )| false
• Search Google Scholar
• Export Citation

Rossi D, Rasi S, Spina V. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 2013;121:1403–1412.

RossiDRasiSSpinaV. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood2013;121:1403–1412. )| false
• Search Google Scholar
• Export Citation

Oscier DG, Rose-Zerilli MJ, Winkelmann N. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood 2013;121:468–475.

OscierDGRose-ZerilliMJWinkelmannN. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood2013;121:468–475. )| false
• Search Google Scholar
• Export Citation

Schnaiter A, Paschka P, Rossi M. NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood 2013;122:1266–1270.

SchnaiterAPaschkaPRossiM. NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood2013;122:1266–1270. )| false
• Search Google Scholar
• Export Citation

Rossi D, Rasi S, Spina V. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. Br J Haematol 2012;158:426–429.

RossiDRasiSSpinaV. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. Br J Haematol2012;158:426–429. )| false
• Search Google Scholar
• Export Citation

Villamor N, Conde L, Martinez-Trillos A. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia 2013;27:1100–1106.

VillamorNCondeLMartinez-TrillosA. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia2013;27:1100–1106. )| false
• Search Google Scholar
• Export Citation

Conte MJ, Bowen DA, Wiseman GA. Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma 2014;55:2079–2084.

ConteMJBowenDAWisemanGA. Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma2014;55:2079–2084. )| false
• Search Google Scholar
• Export Citation

Falchi L, Keating MJ, Marom EM. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood 2014;123:2783–2790.

FalchiLKeatingMJMaromEM. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood2014;123:2783–2790. )| false
• Search Google Scholar
• Export Citation

Rai KR, Sawitsky A, Cronkite EP. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219–234.

RaiKRSawitskyACronkiteEP. Clinical staging of chronic lymphocytic leukemia. Blood1975;46:219–234. )| false
• Search Google Scholar
• Export Citation

Binet J, Auquier A, Dighiero G. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198–206.

BinetJAuquierADighieroG. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer1981;48:198–206. )| false
• Search Google Scholar
• Export Citation

Cheson BD, Bennett JM, Grever M. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990–4997.

ChesonBDBennettJMGreverM. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood1996;87:4990–4997. )| false
• Search Google Scholar
• Export Citation

Cheson BD, Byrd JC, Rai KR. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 2012;30:2820–2822.

ChesonBDByrdJCRaiKR. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol2012;30:2820–2822. )| false
• Search Google Scholar
• Export Citation

Chanan-Khan A, Miller KC, Lawrence D. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer 2011;117:2127–2135.

Chanan-KhanAMillerKCLawrenceD. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer2011;117:2127–2135. )| false
• Search Google Scholar
• Export Citation

Byrd JC, Furman RR, Coutre SE. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369:32–42.

ByrdJCFurmanRRCoutreSE. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med2013;369:32–42. )| false
• Search Google Scholar
• Export Citation

Furman RR, Sharman JP, Coutre SE. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997–1007.

FurmanRRSharmanJPCoutreSE. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med.2014;370:997–1007. )| false
• Search Google Scholar
• Export Citation

Woyach JA, Smucker K, Smith LL. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood 2014;123:1810–1817.

WoyachJASmuckerKSmithLL. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood2014;123:1810–1817. )| false
• Search Google Scholar
• Export Citation

Kovacs G, Boettcher S, Bahlo J. Value of minimal residual disease (MRD) negative status at response evaluation in chronic lymphocytic leukemia (CLL): combined analysis of two phase III studies of the German CLL Study Group (GCLLSG) [abstract]. Blood 2014;124:Abstract 23.

KovacsGBoettcherSBahloJ. Value of minimal residual disease (MRD) negative status at response evaluation in chronic lymphocytic leukemia (CLL): combined analysis of two phase III studies of the German CLL Study Group (GCLLSG) [abstract]. Blood2014;124:Abstract 23. )| false
• Search Google Scholar
• Export Citation

Burger JA, Montserrat E. Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood 2013;121:1501–1509.

BurgerJAMontserratE. Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood2013;121:1501–1509. )| false
• Search Google Scholar
• Export Citation

Fowler N, Davis E. Targeting B-cell receptor signaling: changing the paradigm. Hematology Am Soc Hematol Educ Program 2013;2013:553–560.

FowlerNDavisE. Targeting B-cell receptor signaling: changing the paradigm. Hematology Am Soc Hematol Educ Program2013;2013:553–560. )| false
• Search Google Scholar
• Export Citation

Goede V, Fischer K, Busch R. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014;370:1101–1111.

GoedeVFischerKBuschR. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med2014;370:1101–1111. )| false
• Search Google Scholar
• Export Citation

Flynn JM, Byrd JC, Kipps TJ. Obinutuzumab (GA101) 1,000 mg versus 2,000 mg in patients with chronic lymphocytic leukemia (CLL): results of the phase II GAGE (GAO4768g) trial [abstract]. J Clin Oncol 2014;32(Suppl 15):Abstract 7083.

FlynnJMByrdJCKippsTJ. Obinutuzumab (GA101) 1,000 mg versus 2,000 mg in patients with chronic lymphocytic leukemia (CLL): results of the phase II GAGE (GAO4768g) trial [abstract]. J Clin Oncol2014;32(Suppl 15):Abstract 7083. )| false
• Search Google Scholar
• Export Citation

Robak T, Janssens A, Govindbabu K. Ofatumumab + chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study complement 1 (OMB110911) [abstract]. Blood 2013;122:Abstract 528.

RobakTJanssensAGovindbabuK. Ofatumumab + chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study complement 1 (OMB110911) [abstract]. Blood2013;122:Abstract 528. )| false
• Search Google Scholar
• Export Citation

O’Brien S, Furman RR, Coutre SE. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 2014;15:48–58.

O’BrienSFurmanRRCoutreSE. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol2014;15:48–58. )| false
• Search Google Scholar
• Export Citation

O’Brien SM, Furman RR, Coutre SE. Independent evaluation of ibrutinib efficacy 3 years post-initiation of monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic leukemia including deletion 17p disease [abstract]. J Clin Oncol 2014;32(15_suppl):Abstract 7014.

O’BrienSMFurmanRRCoutreSE. Independent evaluation of ibrutinib efficacy 3 years post-initiation of monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic leukemia including deletion 17p disease [abstract]. J Clin Oncol2014;32(15_suppl):Abstract 7014. )| false
• Search Google Scholar
• Export Citation

Wiestner A, Farooqui M, Valdez J. Single agent ibrutinib (PCI-32765) is highly effective in chronic lymphocytic leukaemia patients with 17p deletion [abstract]. Hematol Oncol 2013;31(Suppl 1):98 (Abstract 008).

WiestnerAFarooquiMValdezJ. Single agent ibrutinib (PCI-32765) is highly effective in chronic lymphocytic leukaemia patients with 17p deletion [abstract]. Hematol Oncol2013;31(Suppl 1):98(Abstract 008). )| false
• Search Google Scholar
• Export Citation

Zelenetz AD, Lamanna N, Kipps TJ. A phase 2 study of idelalisib monotherapy in previously untreated patients ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [abstract]. Blood 2014;124:Abstract 1986.

ZelenetzADLamannaNKippsTJ. A phase 2 study of idelalisib monotherapy in previously untreated patients ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [abstract]. Blood2014;124:Abstract 1986. )| false
• Search Google Scholar
• Export Citation

O’Brien S, Lamanna N, Kipps TJ. Update on a phase 2 study of idelalisib in combination with rituximab in treatment-naïve patients ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [abstract]. Blood 2014;124:Abstract 1994.

O’BrienSLamannaNKippsTJ. Update on a phase 2 study of idelalisib in combination with rituximab in treatment-naïve patients ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [abstract]. Blood2014;124:Abstract 1994. )| false
• Search Google Scholar
• Export Citation

Brown JR, Byrd JC, Coutre SE. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014;123:3390–3397.

BrownJRByrdJCCoutreSE. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood2014;123:3390–3397. )| false
• Search Google Scholar
• Export Citation

Advani RH, Buggy JJ, Sharman JP. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31:88–94.

AdvaniRHBuggyJJSharmanJP. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol2013;31:88–94. )| false
• Search Google Scholar
• Export Citation

Byrd JC, Brown JR, O’Brien S. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014;371:213–223.

ByrdJCBrownJRO’BrienS. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med2014;371:213–223. )| false
• Search Google Scholar
• Export Citation

Brown JR, Hillmen P, O’Brien S. Updated efficacy including genetic and clinical subgroup analysis and overall safety in the phase 3 RESONATETM trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma [abstract]. Blood 2014;124:Abstract 3331.

BrownJRHillmenPO’BrienS. Updated efficacy including genetic and clinical subgroup analysis and overall safety in the phase 3 RESONATETM trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma [abstract]. Blood2014;124:Abstract 3331. )| false
• Search Google Scholar
• Export Citation

O’Brien S, Jones JA, Coutre S. Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: results from the phase II RESONATE™-17 trial [abstract]. Blood 2014;124:Abstract 327.

O’BrienSJonesJACoutreS. Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: results from the phase II RESONATE™-17 trial [abstract]. Blood2014;124:Abstract 327. )| false
• Search Google Scholar
• Export Citation

Sharman JP, Coutre SE, Furman RR. Second interim analysis of a phase 3 study of idelalisib (ZYDELIG®) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors [abstract]. Blood 2014;124:Abstract 330.

SharmanJPCoutreSEFurmanRR. Second interim analysis of a phase 3 study of idelalisib (ZYDELIG®) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors [abstract]. Blood2014;124:Abstract 330. )| false
• Search Google Scholar
• Export Citation

Sharman JP, Coutre SE, Furman RR. Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: results from a phase 3, randomized, double-blind, placebo-controlled trial [abstract]. J Clin Oncol 2014;32(15_suppl):Abstract 7011.

SharmanJPCoutreSEFurmanRR. Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: results from a phase 3, randomized, double-blind, placebo-controlled trial [abstract]. J Clin Oncol2014;32(15_suppl):Abstract 7011. )| false
• Search Google Scholar
• Export Citation

Wierda WG, Kipps TJ, Mayer J. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749–1755.

WierdaWGKippsTJMayerJ. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol2010;28:1749–1755. )| false
• Search Google Scholar
• Export Citation

Wierda WG, Kipps TJ, Mayer J. Final analysis from the international trial of single-agent ofatumumab in patients with fludarabine-refractory chronic lymphocytic leukemia [abstract]. Blood 2010;116:Abstract 921.

WierdaWGKippsTJMayerJ. Final analysis from the international trial of single-agent ofatumumab in patients with fludarabine-refractory chronic lymphocytic leukemia [abstract]. Blood2010;116:Abstract 921. )| false
• Search Google Scholar
• Export Citation

Wierda WG, Padmanabhan S, Chan GW. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase II international study. Blood 2011;118:5126–5129.

WierdaWGPadmanabhanSChanGW. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase II international study. Blood2011;118:5126–5129. )| false
• Search Google Scholar
• Export Citation

Cartron G, de Guibert S, Dilhuydy MS. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood 2014;124:2196–2202.

CartronGde GuibertSDilhuydyMS. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood2014;124:2196–2202. )| false
• Search Google Scholar
• Export Citation

Goede V, Engelke A, Fischer K. Salvage therapy with obinutuzumab (GA101) plus chlorambucil (Clb) after treatment failure of Clb alone in patients with chronic lymphocytic leukemia (CLL) and comorbidities: results of the CLL11 study [abstract]. Blood 2014;124:Abstract 3327.

GoedeVEngelkeAFischerK. Salvage therapy with obinutuzumab (GA101) plus chlorambucil (Clb) after treatment failure of Clb alone in patients with chronic lymphocytic leukemia (CLL) and comorbidities: results of the CLL11 study [abstract]. Blood2014;124:Abstract 3327. )| false
• Search Google Scholar
• Export Citation

Gribben JG, Zahrieh D, Stephans K. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 2005;106:4389–4396.

GribbenJGZahriehDStephansK. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood2005;106:4389–4396. )| false
• Search Google Scholar
• Export Citation

Khouri IF, Keating MJ, Saliba RM, Champlin RE. Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy 2002;4:217–221.

KhouriIFKeatingMJSalibaRMChamplinRE. Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy2002;4:217–221. )| false
• Search Google Scholar
• Export Citation

Sorror ML, Storer BE, Sandmaier BM. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008;26:4912–4920.

SorrorMLStorerBESandmaierBM. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol2008;26:4912–4920. )| false
• Search Google Scholar
• Export Citation

Khouri IF, Saliba RM, Admirand J. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 2007;137:355–363.

KhouriIFSalibaRMAdmirandJ. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol2007;137:355–363. )| false
• Search Google Scholar
• Export Citation

Moreno C, Villamor N, Colomer D. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 2005;23:3433–3438.

MorenoCVillamorNColomerD. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol2005;23:3433–3438. )| false
• Search Google Scholar
• Export Citation

Schetelig J, van Biezen A, Brand R. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol 2008;26:5094–5100.

ScheteligJvan BiezenABrandR. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol2008;26:5094–5100. )| false
• Search Google Scholar
• Export Citation

Dreger P, Dohner H, Ritgen M. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010;116:2438–2447.

DregerPDohnerHRitgenM. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood2010;116:2438–2447. )| false
• Search Google Scholar
• Export Citation

Tsimberidou AM, Keating MJ. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer 2009;115:2824–2836.

TsimberidouAMKeatingMJ. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer2009;115:2824–2836. )| false
• Search Google Scholar
• Export Citation

National Cancer Institute. SEER Stat Fact Sheets: Chronic Lymphocytic Leukemia. Bethesda, MD: 2012. Available at: http://seer.cancer.gov/statfacts/html/clyl.html. Accessed August 2012.

National Cancer Institute. SEER Stat Fact Sheets: Chronic Lymphocytic Leukemia. Bethesda, MD: 2012. Available at: http://seer.cancer.gov/statfacts/html/clyl.html. Accessed August 2012. )| false
• Search Google Scholar
• Export Citation

Eichhorst B, Goede V, Hallek M. Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:171–178.

EichhorstBGoedeVHallekM. Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma2009;50:171–178. )| false
• Search Google Scholar
• Export Citation

Eichhorst BF, Busch R, Stilgenbauer S. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009;114:3382–3391.